Sinonasal Microbial Composition for Chronic Sinusitis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic sinusitis, rhinitis, and rhinosinusitis often fail to provide long-term relief, leading to recurrent symptoms and frequent medical therapy or surgery, with side effects from antibiotics and steroids posing additional health risks.
Innovation Solution
A method involving the administration of a substantially complete sinonasal microbial composition comprising Actinobacteria, Bacteroidetes, Firmicutes, or Proteobacteria, derived from healthy donor mucosal fluid, processed to ensure pathogen absence and viability, is used to reduce symptoms and recurrence of these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics and corticosteroids are administered to treat chronic sinusitis, then symptom relief is achieved, but side effects and health risks increase
Solution Approach 1:
The patent converts the harmful overgrowth of pathogenic bacteria into a beneficial treatment approach by administering a composition containing beneficial sinonasal microbes. These beneficial microbes compete with and displace pathogenic bacteria, thereby eliminating the need for harmful antibiotics while achieving similar therapeutic effects of reducing bacterial overgrowth and inflammation in the sinonasal cavities.
Solution Approach 2:
The treatment composition utilizes the patient's own sinusoidal microbiota and beneficial bacteria to restore and maintain a healthy microbial balance. The composition contains beneficial microbes that naturally colonize the sinonasal cavities and self-regulate the microbial ecosystem, eliminating the need for external pharmaceutical interventions and their associated side effects.
2Reliability
If repeated medical therapy and surgery are performed, then disease control is achieved, but recurrence frequency increases
Solution Approach 1:
The patent applies preliminary action by administering the microbial composition before disease recurrence occurs. The composition prevents pathogenic bacterial overgrowth by establishing a protective microbial ecosystem in advance, thereby preventing disease recurrence rather than merely treating symptoms after they manifest, which reduces the need for repeated medical therapy and surgery.
Solution Approach 2:
The treatment establishes a continuous protective effect by introducing beneficial microbes that continuously compete with and displace pathogenic bacteria. This continuous microbial competition maintains disease control over time, reducing recurrence frequency compared to intermittent medical therapy and surgery that provides only temporary relief.
3Duration of action of moving object
If standard treatments are administered, then acute symptom relief is achieved, but long-term effectiveness decreases
Solution Approach 1:
The patent transitions from static symptom relief to dynamic microbial ecosystem modulation. The treatment composition dynamically restores and maintains a healthy microbial balance in the sinonasal cavities, enabling the body's own immune system to continuously respond adaptively to prevent pathogenic overgrowth. This dynamic microbial competition provides sustained long-term effectiveness rather than temporary acute relief.
Data Source
AI summary
Provided are methods to treat upper respiratory tract inflammatory diseases and conditions including (chronic) sinusitis, (chronic) rhinitis, and/or (chronic) rhinosinusitis (with or without polyps), as well as nasal polyposis. Further provided are substantially complete sinonasal microbial compositions, methods of producing same, and medical kits comprising same.